Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Osaka, OsakaFounded 18991,753 employeesWebsite
Holds the world's leading share in OTC eye drops and boasts strong skincare brands. Expanding into regenerative medicine and wellness-related businesses.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Japan Market | 50% | ¥169.3B | ¥22.1B | 13.1% |
| Asia | 37% | ¥125.3B | ¥15.0B | 12.0% |
| Europe Regional Business | 7% | ¥23.9B | ¥1.0B | 4.2% |
| Americas Regional Business | 6% | ¥21.6B | ¥1.7B | 7.9% |
Close (Oct 30, 2026)
¥2,740+16.3% (1Y)
Rohto +16.3% over 1Y, 3.9pt above the industry average (23 companies, +12.4%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥343.7B | ¥41.1B | ¥34.2B | ¥485.8B | +11.4% |
| 2025FY | ¥308.6B | ¥38.9B | ¥31.0B | ¥421.9B | +14.0% |
| 2024FY | ¥270.8B | ¥40.0B | ¥30.9B | ¥346.2B | +13.5% |
| 2023FY | ¥238.7B | ¥34.0B | ¥26.4B | ¥309.7B | +19.5% |
| 2022FY | ¥199.6B | ¥29.0B | ¥21.1B | ¥274.9B | +10.1% |
| 2021FY | ¥181.3B | ¥23.0B | ¥16.7B | ¥226.1B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
